Protagenic Therapeutics Market Cap ($1.43 Million)
Market Cap & Net Worth: Protagenic Therapeutics (PTIX)
Protagenic Therapeutics market cap. Protagenic Therapeutics (NASDAQ:PTIX) has a market capitalization of $1.43 Million ($1.43 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30380 globally and #6197 in its home market, demonstrating a -17.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Protagenic Therapeutics's stock price $0.83 by its total outstanding shares 1810208 (1.81 Million). Also see Protagenic Therapeutics cash flow conversion for how efficiently the company converts equity into cash flow.
Protagenic Therapeutics Market Cap History (2015–2026)
Protagenic Therapeutics market cap history from 2015 to 2026. Data shows change from $22.39 Million to $1.50 Million (-31.25% CAGR). Check Protagenic Therapeutics (PTIX) stock price for real-time trading data and today's change.
Index Memberships
Protagenic Therapeutics is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.00% | #887 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #2820 of 3165 |
Weight: Protagenic Therapeutics's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Protagenic Therapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Protagenic Therapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore PTIX net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PTIX by Market Capitalization
Companies near Protagenic Therapeutics in the global market cap rankings as of November 3, 2026. Also see Protagenic Therapeutics asset portfolio for a full breakdown of the balance sheet.
Key companies related to Protagenic Therapeutics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Protagenic Therapeutics (2015–2026)
Market capitalization of Protagenic Therapeutics from 2015 to today. Between 2015 and today, Protagenic Therapeutics's market cap moved from $22.39 Million to $ 1.50 Million, with a yearly change of -31.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.50 Million | -36.15% |
| 2025 | $2.35 Million | +165.31% |
| 2024 | $887.00K | -50.51% |
| 2023 | $1.79 Million | -38.12% |
| 2022 | $2.90 Million | -71.12% |
| 2021 | $10.03 Million | +31.90% |
| 2020 | $7.60 Million | -25.54% |
| 2019 | $10.21 Million | -29.50% |
| 2018 | $14.48 Million | -9.09% |
| 2017 | $15.93 Million | -71.55% |
| 2016 | $55.99 Million | +150.00% |
| 2015 | $22.39 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Protagenic Therapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.43 Million USD |
| MoneyControl | $1.43 Million USD |
| MarketWatch | $1.43 Million USD |
| marketcap.company | $1.43 Million USD |
| Reuters | $1.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.